Single-nucleotide Polymorphisms in the p53 Signaling Pathway
- 9 December 2009
- journal article
- review article
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Biology
- Vol. 2 (5), a001032
- https://doi.org/10.1101/cshperspect.a001032
Abstract
The p53 tumor suppressor pathway is central both in reducing cancer frequency in vertebrates and in mediating the response of commonly used cancer therapies. This article aims to summarize and discuss a large body of evidence suggesting that the p53 pathway harbors functional inherited single-nucleotide polymorphisms (SNPs) that affect p53 signaling in cells, resulting in differences in cancer risk and clinical outcome in humans. The insights gained through these studies into how the functional p53 pathway SNPs could help in the tailoring of cancer therapies to the individual are discussed. Moreover, recent work is discussed that suggests that many more functional p53 pathway SNPs are yet to be fully characterized and that a thorough analysis of the functional human genetics of this important tumor suppressor pathway is required.Keywords
This publication has 100 references indexed in Scilit:
- A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder CancerClinical Cancer Research, 2007
- Haplotype structure and selection of the MDM2 oncogene in humansProceedings of the National Academy of Sciences of the United States of America, 2007
- A common coding variant in CASP8 is associated with breast cancer riskNature Genetics, 2007
- Death effector domain DEDa, a self-cleaved product of caspase-8/Mch5, translocates to the nucleus by binding to ERK1/2 and upregulates procaspase-8 expression via a p53-dependent mechanismThe EMBO Journal, 2007
- The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li–Fraumeni syndrome and related phenotypesEuropean Journal of Human Genetics, 2006
- MDM2 SNP309 accelerates colorectal tumour formation in womenJournal of Medical Genetics, 2006
- TheATMmissense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancerHuman Mutation, 2006
- A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in HumansCell, 2004
- Analysis of CDKN1A polymorphisms: markers of cancer susceptibility?Cancer Genetics and Cytogenetics, 2003
- Mdm2 promotes the rapid degradation of p53Nature, 1997